Elicio Therapeutics, Inc. ELTX · Stock Open Elicio Therapeutics, Inc. in new tab
Analyst price targets
Recent rating changes, newest first
Elicio Therapeutics, Inc. Analysis (ELTX)
Is Elicio Therapeutics, Inc. a good investment? Elicio Therapeutics, Inc. (ELTX) is currently trading at 1.89 USD. Market analysts have a consensus price target of 13.67 USD. This suggests a potential upside from current levels.
Earnings Schedule: Elicio Therapeutics, Inc. is expected to release its next earnings report on Nov. 12, 2026. The market consensus estimate for Forward EPS is -1.69.
Investor FAQ
Does Elicio Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Elicio Therapeutics, Inc.?
Elicio Therapeutics, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 12, 2026. The company currently has a trailing EPS of -2.16.
Company Profile
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
| Split Date | Split Ratio to 1 |
|---|---|
| June 2, 2023 | 1:10 |
Community Discussion